Walden University

ScholarWorks
Walden Dissertations and Doctoral Studies

Walden Dissertations and Doctoral Studies
Collection

2021

Effects of Hepatitis on Human Immunodeficiency Virus Viral
Suppression
Andrenita Checoby West
Walden University

Follow this and additional works at: https://scholarworks.waldenu.edu/dissertations
Part of the Epidemiology Commons
This Dissertation is brought to you for free and open access by the Walden Dissertations and Doctoral Studies
Collection at ScholarWorks. It has been accepted for inclusion in Walden Dissertations and Doctoral Studies by an
authorized administrator of ScholarWorks. For more information, please contact ScholarWorks@waldenu.edu.

Walden University
College of Health Professions

This is to certify that the doctoral dissertation by

Andrenita Toson West

has been found to be complete and satisfactory in all respects,
and that any and all revisions required by
the review committee have been made.

Review Committee
Dr. Patrick Bassey Williams, Committee Chairperson, Public Health Faculty
Dr. Lee Caplan, Committee Member, Public Health Faculty
Dr. Mary Lou Gutierrez, University Reviewer, Public Health Faculty

Chief Academic Officer and Provost
Sue Subocz, Ph.D.

Walden University
2021

Abstract
Effects of Hepatitis on Human Immunodeficiency Virus Viral Suppression
by
Andrenita Toson West

MPH, Morehouse School of Medicine, 2011
BS, Georgia State University, 2007

Dissertation Submitted in Partial Fulfillment
of the Requirements for the Degree of
Doctor of Philosophy
Public Health

Walden University
February 2021

Abstract
Coinfection with human immunodeficiency virus (HIV) and viral hepatitis leads to
unfavorable health outcomes, making treatment of HIV difficult and increasing the odds
of HIV transmission. The purpose of this study is to assess whether viral hepatitis (B and
C) hinders HIV viral suppression and impacts the white blood cell count (CD4) when a
person is concurrently infected with both viruses. The syndemics theory guided this
study. Two research questions tested whether there was an association between
coinfection with viral hepatitis and HIV viral load suppression. The research design was
quantitative case-control with secondary data from 65,626 reports of HIV, HBV, and
HCV at the Georgia Department of Public Health. Descriptive statistics and measures of
association indicated that a coinfection with HBV or HCV was determined to be
significantly associated with HIV viral load suppression. Persons coinfected with
HBV/HIV were 1.45 times more likely to have achieved HIV viral load suppression than
persons who were only infected with HIV (OR= 1.45, 95% CI 1.32-1.59, p= .0001).
Those coinfected with HCV/HIV were 1.55 times more likely to have achieved HIV viral
load suppression than those only infected with HIV (OR= 1.55, 95% CI 1.44-1.67,
p=.0001). Coinfection with HBV was found to have a greater impact on CD4 cell counts,
making persons infected with HBV/HIV 1.45 times more likely to be AIDS defining than
HCV in individuals infected with HIV (OR= 1.45, 95% CI 1.34-1.67, p= .0001). Positive
social change implications may include use of findings to support future prevention and
control strategies in the coinfected population aimed at decreasing or controlling the
spread of HIV and other sexually transmitted infections in the United States.
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Chapter 1: Introduction to the Study
Introduction
Viral hepatitis is a group of communicable diseases that affects the liver by
causing inflammation (CDC, 2014). The most common types of viral hepatitis in the
United States are hepatitis A (HAV), hepatitis B (HBV), and hepatitis C (HCV; CDC,
2014]. In the United States, there are between 2.2 and 4.7 million people infected with
viral hepatitis, many of whom are not aware they are infected (HHS, 2020).
Currently in 2020, viral hepatitis is the leading cause of liver cancer in the US
(HHS, 2020). Liver cancer and other liver-related diseases resulting from long term liver
damage secondary to untreated viral hepatitis affect approximately 4.4 million Americans
nationwide (CDC, 2014). In the US, certain populations are more affected by viral
hepatitis than others (HHS, 2013). Persons living with HIV/AIDS (PLWHA) are among
those populations who are disproportionally affected by viral hepatitis (HHS, 2013).
Human immunodeficiency virus (HIV) is a virus that attacks the body’s immune
system. The infection is known to cause the selective loss of CD4 cells due to virus
replication and subsequent cell destruction which causes the body to become more
susceptible to other infections or infection-related cancers (DHHS Panel on Antiretroviral
Guidelines for Adults and Adolescents, 2015). CD4 cell count is often used as an
important measure of HIV progression and as one of the indications for treatment
initiation (WHO, 2013). When the CD4 count drops below 200ml, a person is diagnosed
with AIDS. A normal range for CD4 cells is about 500 to 1,500. The higher the CD4
count, the better.
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While effective antiretroviral treatment (ART) can significantly increase CD4 cell
counts in most patients, there are certain populations who remain at comparatively low
CD4 cell count levels (Kaufmann et al., 2013). Factors associated with poor CD4
recovery have been extensively studied; examples of these factors include older age,
ongoing HIV replication (Kaufmann et al., 2013), treatment disruption and nonadherence to combined anti-retroviral therapy (cART) (Kaufmann et al., 2011), and late
initiation of treatment (Tarwater et al., 2001). Since CD4 level forecasts mortality, and
low CD4 cell count is associated with an increased risk of opportunistic infections, it is
important to explore all possible factors that hinder immune recovery among HIV
infected people (Lewden et al., 2007).
The HIV viral load is a measurement of the amount of HIV circulating in the
blood. The goal of HIV therapy is to prevent HIV from replicating in order to bring the
viral population down to an undetectable level. When a person living with HIV begins an
ART regimen, his/her viral load drops. For almost everyone who adheres to his/her HIV
medication as recommended, their HIV viral load will drop to an undetectable level in six
months or less. This phenomenon is termed viral suppression. Continuing to take HIV
medications as directed is imperative to stay virally undetectable or suppressed.
Although a person’s viral load is undetectable, HIV is still present in the body. The virus
lays dormant inside a small number of cells in the body. However, persons who achieve
and maintain viral suppression have effectively no risk of sexually transmitting the virus.
The aim of HIV therapy is to sustain viral suppression for many years, which not only
preserves future treatment options but reduces the risk of serious illness by 53%. Once
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ART is stopped, the virus will return to a detectable level and start replicating again.
HIV viral suppression is a powerful predictor of CD4 T-cell gains. HIV viral suppression
is also important for people living with HIV to stay healthy, have improved quality of
life, and live longer.
Approximately 1.1 million people in the United States are living with HIV, and
about 15% of them are not aware of their infection status (Mugavero et al., 2013). HIV
and viral hepatitis share common modes of transmission, which include blood (most
commonly through injection drug use) and unprotected sexual contact. Because of their
common transmission modes, coinfections by these viruses is common (Alter, 2014).
Significant proportions of PLWHA are coinfected with HCV, and others are chronically
infected with HBV (Soriano et al., 2010). According to the Centers for Disease Control
and Prevention (CDC), approximately one-third of HIV infected individuals are
coinfected with hepatitis (HHS, 2013). This estimate equates to about 25% having
HIV/HCV coinfections and about 10% having HIV/HBV coinfections (HHS, 2013).
Problem Statement
Medical comorbidities resulting in greater risk of liver cancer include obesity,
diabetes mellitus, insulin resistance, hepatitis B virus infection and HIV infection
(Chopra, 2014). Since persons infected with HIV are immunocompromised, the
progression of viral hepatitis is accelerated to end-stage liver disease and hepatocellular
carcinoma more than in those who are only infected with hepatitis (Vellozzi et al., 2011).
Evidence suggests that HIV negatively impacts infections of HBV and HCV.
Chopra (2014) suggested that when HIV is concurrently present with an HCV infection,
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HIV speeds the progression of liver disease. Chun et al. (2012) also suggested that HIV
has an adverse impact on HBV liver disease progression as well as an increased risk of
liver cirrhosis.
Although an increasing number of HIV-infected persons are taking ART, many
do not achieve HIV viral suppression and remain at risk for Acquired Immune Deficiency
Syndrome (AIDS) and more likely to transmit HIV. Understanding if HBV or HCV has a
potential impact on HIV is limited. Taylor et al. (2012) previously suggested that a
coinfection with HIV and viral hepatitis can lead to unfavorable health outcomes, making
treatment of HIV difficult and increasing the risk of HIV transmission. However, Taylor
et al.’s study did not consider how viral hepatitis impacts HIV CD4 cell counts nor HIV
viral load suppression. This study assessed if viral hepatitis leads to unfavorable
outcomes in HIV-infected persons by hindering the achievement of HIV viral
suppression or by impacting HIV CD4 cell counts.
Purpose of the Study
The purpose of this quantitative, case control study was to assess if viral hepatitis
(B and C) hinders HIV viral suppression and impacts CD4 count when a person is
concurrently infected with both viruses.
Research Questions
The following are the research questions for this study:
RQ1: Is there an association between coinfection with viral hepatitis and HIV
viral load suppression in HIV positive individuals?
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Ho1: There is no association between coinfection with viral hepatitis and HIV
viral load suppression in HIV positive individuals.
Ha1: There is an association between coinfection with viral hepatitis and HIV
viral load suppression in HIV positive individuals.
RQ2: Does the type of viral hepatitis (HBV or HCV) impact the CD4 count of the
HIV infection?
Ho2: The type of viral hepatitis (HBV or HCV) does not impact the CD4 count of
the HIV infection.
Ha2: The type of viral hepatitis (HBV or HCV) impacts the CD4 count of the HIV
infection.
Theoretical Framework
This study was guided by the syndemics theory (Singer & Clair, 2003). The
theory is used to understand the synergistic interactions of two or more diseases as they
exist within the population with the presence of social and biological conditions. It is a
valuable tool in the public health fight against HIV (Douglas-Vail, 2015). There are three
constructs to this theory: (a) populations of interest, (b) social contexts shaping disease,
and (c) biological synergism. The first construct requires that the two diseases of synergy
must cluster in the same population to provide an opportunity for coinfection. The second
construct encompasses the social conditions that influence individual and population
health. The third construct occurs within the body of the individual when the two diseases
are present. According to Singer and Clair (2003), actual biological synergism must occur
between the two diseases (HIV and hepatitis), resulting in excess disease burden. There
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are seven broad ways in which synergistic diseases interact within the body; they are
enhanced contagiousness, accelerated virulence, greater expression of symptoms,
physical alterations of the body’s immunology, alterations of emotions, and gene
assortment between pathogens and iatrogenic interactions (Klein, 2011). This study
focused on two of them, accelerated virulence and physical alterations of the body’s
immunology. The two interactions guided this study by showing how the syndemic
interaction of HIV, HBV, and HCV influence HIV viral suppression by increasing the
amount of the HIV virus present in the body or by decreasing the CD4 count, thus
inhibiting the achievement of HIV viral suppression.
Nature of the Study
This quantitative study had a case-control research design. In a case-control study,
the outcome of interest is already known, and the researcher traces back to establish a
relationship between the outcome and possible risk factors (Frankfort-Nachmias &
Nachmias, 2008). In this study, the data were based on individuals that already have HIV,
HIV/HCV, or HIV/HBV and are reported in Georgia’s Department of Public Health
disease registries. A case-control design was appropriate for this type of study, because it
is cost effective and timesaving and does not expose subjects to harm due to intervention
effects. Case-control designs are also suitable for the analysis of multiple exposures, and
more so in the investigation of rare diseases (Aschengrau & Seage III, 2014).
Definitions of Terms
CD4 cells: a type of white blood cell that fights infection in the body. In HIV infection,
the virus destroys CD4 cells, lowering the body’s defenses to infection.
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Comorbid infection or Coinfection: the presence of multiple infections in a host by
multiple infectious agents (Cox, 2001).
Electronic HIV and AIDS Surveillance System (eHARS): a web-based tool supported and
developed by the CDC for state and local health departments for HIV/AIDS surveillance.
Hepatitis: inflammation of the liver. The most common causes of viral hepatitis in the US
are HAV, HBV, and HCV. HBV and HCV are common among those people who are at
risk for or living with HIV (Alter, 2006).
HIV: a virus that causes the HIV infections and over time may cause AIDS.
State Electronic Notifiable Disease Surveillance System (SENDSS): created for the
Georgia Department of Public Health (GDPH) for the reporting and surveillance of all
notifiable diseases in Georgia.
Viral Load (VL): the amount of HIV in an infected person’s blood. The higher the HIV
level in the blood, the higher the VL, and the greater the risk the person has of becoming
ill due to HIV. It is useful for measuring sustained response to ART (DHHS Panel on
Antiretroviral Guidelines for Adults and Adolescents, 2015).
Viral Suppression: HIV-1 viral load of less than 200 copies on the most recent VL test.
Having viral suppression significantly decreases the rate of HIV transmission (Loutfy et
al., 2013).
Antiretroviral Therapy (ART): the use of HIV medicines to treat HIV infection. It is
recommended for everyone who has HIV. ART helps people with HIV live longer,
healthier lives and reduces the risk of HIV transmission.
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Highly Active Antiretroviral Therapy (HAART): a form of treatment that uses a
combination of three or more drugs to treat HIV infection.
Assumptions
Data collected by the GDPH were used to evaluate the hypotheses. The data set
only contained persons living in Georgia at the time of diagnosis with either HIV or
hepatitis. Because I did not collect the data, the accuracy of the data can only be assumed.
Records cannot be reviewed for accuracy; however, GDPH has quality measures in place
to ensure the validity and integrity of the data submitted. Therefore, I assumed that the
quality measures in place are accurate and can minimize potential transcription error.
A second assumption was that the data used in this study contained all reports of
HIV and hepatitis in Georgia. Because HIV and hepatitis are reportable diseases in
Georgia, it is required that all diagnosed diseases are reported to GDPH. Thus, it was
assumed that the database contained all known adult disease diagnoses in the state.
Scope and Delimitations
The scope of this study was to compare the CD4 cell counts and HIV VLs of
persons coinfected with HIV and HCV/HBV to those of persons who were only infected
with HIV to assess whether HCV/HBV affects the achievement of viral suppression as
well as to assess which type of hepatitis, B or C, is more virulent to the HIV infection by
evaluating CD4 cell counts for a determination of AIDS.
Limitations
One limitation of this study was the data. There may have been missing laboratory
data because of inadequate reporting, inadequate processing, or laboratory tests
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performed outside of Georgia. All registered are mandated by state law to report
laboratory results on HIV-related laboratory test to the Georgia DPH. However, some
facilities may not comply or send only some test results and not others. This can result in
an underestimation of the coinfected cases in Georgia. Another limitation is that the
results of this study may not be generalizable, since the data were only collected from the
coinfected population. The results, however, can be used as a reference point to other
studies of the same population.
Significance
The goal of this study was to determine if HBV and HCV have an impact on HIV
viral suppression and CD4 cell count among HIV/HBV and HIV/HCV coinfected
persons. The HIV/viral hepatitis coinfection is a growing and evolving epidemic (Taylor
et al., 2012). HBV and HCV are highly prevalent among the HIV infected population
(Taylor et al., 2012). People with HIV who are coinfected with either HBV or HCV have
an increased risk of life-threatening complications (CDC, 2014). Therefore, it is essential
that health professionals be informed on how viral suppression and increased CD4 cell
counts can be achieved in coinfected populations. When viral load is controlled (or
suppressed), the risk of HIV transmission to others is greatly lowered (Mugavero et al.,
2013). This study could potentially be used to support future prevention and control
strategies in the co-infected population aimed at decreasing or controlling the spread of
HIV and other STIs in the United States. These strategies may increase individual
knowledge of HIV, HBV, and HCV statuses, prevent new infections among HIV
negative persons, reduce transmission from persons living with HIV, and enhance
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response capacity and intensive data-to-care activities to support sustained viral
suppression. The results may also provide insight on whether a coinfection with HBV or
HCV affects HIV viral suppression in a person infected with HIV, which can be used to
improve health outcomes for persons living with HIV through increasing screenings and
provide better access to care.
Summary
The purpose of this study was to examine if either or both HBV and HCV affect
HIV viral suppression in a person who is infected with HIV. This study used quantitative
methodology. Data were extracted from the eHARS and SENDSS databases of the
GDPH. The study was grounded by the syndemics theory (Singer & Clair, 2003), which
allows researchers to investigate the synergistic interactions of two or more diseases as
they coexist within the population alongside social and biological conditions. The results
of this study may potentially be used to improve the health outcomes of persons living
with HIV/AIDS.
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Chapter 2: Literature Review
Introduction
The use of ART has led to great reductions in HIV related morbidity and
mortality in HIV infected individuals (Cooper & Cameron, 2014). However, alongside
ART’s success has been the succeeding emergence of comorbidities, such as STIs. In the
presence of an STI, HIV may be transmitted at a rate that is up to five times greater than
in a person who does not have an STI (Mehendale et al., 2015).
HCV and HBV, due to their high presence in the HIV positive population, are
among the leading causes of morbidity and mortality in the HIV positive population
(Matthews et al., 2014). The hepatitis viruses have been known for their potential
association with poor HIV health outcomes (Matthews et al., 2014). Coinfection of HIV
positive individuals with HBV and HCV is a global problem of increasing concern,
despite the availability of successful strategies for both their prevention and treatment.
Several studies have examined the impact of HCV and HBV on HIV. While most have
found that these viruses have no impact on the HIV virologic response to ART, there are
conflicting reports regarding immunologic response.
Literature Search Strategy
I conducted the literature search using the Walden University library’s online
databases and journal articles from the years 2014 until present. First, I ordered the
databases by subject. I searched journals categorized as health sciences and/or nursing.
The databases found to be most useful were Health Sciences: A Sage Full Text Journal,
MEDLINE, and Academic Search Premier. Other databases searched included Google
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Scholar, Health and Medical Complete, and Nursing and Allied Health Source. I
searched each of these databases using the same search terms. I reviewed these databases
multiple times during the search period to identify newly added articles. Several terms
were included in the database searches. HIV was used as well as the expanded name of
human immunodeficiency virus. AIDS and its expanded name acquired immunodeficiency
syndrome were also included. HIV and hepatitis B and hepatitis C were used individually
and in combination. Comorbid infection was also searched with HIV and Hepatitis B and
C. This same search was also conducted using coinfection as a synonym for comorbid
infection. Subsequently, sexually transmitted disease and infection were also used as
search parameters in conjunction with comorbid illness and coinfection to garner some
general articles about the effects of coinfection with a sexually transmitted disease (STD)
on health.
Organization of the Review
First, I review the theoretical framework for the study. Next, background
information on HIV and Hepatitis B and C diseases (treated as separate and unique
infections) is presented. The presentation includes relevant statistics and a summary of
research studies associated with the infections. Following is a general discussion of
HIV/HBV and HIV/HCV coinfection and its associated background, statistics, and
studies. Finally, the literature review concludes with a consideration of the impact of this
work on society.
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Theoretical Framework
The syndemic theory was identified during the mid-1990s by anthropologist
Merrill Singer (Klein, 2011). Singer was the first researcher to identify a syndemic in
public health research (Wilson et al., 2014). Syndemic refers to the tendency for multiple
epidemics to co-occur and interact with one another, with each one worsening the effects
of the others (Singer, 2009). Syndemics occur when health-related problems cluster by
person, place, or time. Syndemic also focuses on health disparities and the social
conditions that affect them. The concept of syndemics represents an acknowledgment of
the fact that many diseases and social problems worsen the effects of others already being
experienced by their host. Syndemics are prevented by the control of each disease that
plays a role in it, as well as the prevention and control of the forces that bound the two
diseases together (Singer & Clair, 2003).
The syndemic theory was created in attempts to identify a “big picture” approach
in epidemiological and public health thinking. Singer wanted to understand the
determinant interconnections among pressing health problems, sufferer and community
understandings of the illness(es)/disease(s) in question, the relevant social, political, and
economic forces in play, and the environmental conditions that contributed to the
development of ill health. The syndemic theory can be conceptualized with the following
components: the populations of interest, social contexts shaping diseases, and biological
synergism.
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The Populations of Interests
The CDC described a syndemic as two or more epidemics in the same population,
interacting to create an opportunity for co-infection and synergism which ultimately lead
to excess burden of disease (Douglas-Vail, 2015). For example, frequently HIV and
Mycobacterium tuberculosis (MTb) are clustered in the same population. When this
happens, opportunities for individuals to be coinfected spiral upward due to the presence
of both in the same population. Researchers have found that coinfection with HIV and
MTb synergically interacts, leading to deadly consequences by lessening the survival
time of coinfected individuals compared to individuals with just HIV or MTb (Dye et al.,
1999). Another example of a synergistic effect can be seen in individuals who are
suffering from asthma, which increases their chances of developing a coinfection with
respiratory syncytial virus and influenza A virus, thus resulting in induced asthma attacks
of greater severity (Zhoe et al., 2009).
Social Contexts Shaping Disease
The term syndemic goes beyond the idea of disease clustering in a particular
location or population. It highlights the importance of the social conditions that influence
the health of individuals and populations. Evidence suggests that social conditions are
closely related to health outcomes (Currie, 2012). According to Currie (2012),
determinants such as socioeconomic status, geographical location, gender, race, ethnicity,
age, diet, water, sanitation, residence, access to health care, discrimination, stress,
violence, and criminal justice systems are some of the social causes of syndemics. Social
contexts outline not only the spread of disease, but also affect access to resources for
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coping with disease burdens (Douglas-Vail, 2015). For example, research has shown that
the HIV/HBV coinfection interaction can lead to poor health outcomes in the coinfected
individual, but Gomez-Gonzalo et al. (2001) underlined that the impact the viruses have
on one another is mediated by individual biology and age, nutritional status, and access to
medical care of the coinfected individual. Another example of social context would be
that individuals living in poverty have an increased likelihood of exposure to TB due to
overcrowding in poorly ventilated habitations. Once infected, these individuals would be
more likely to develop active TB because they are already weakened from other
infections and malnutrition (Douglas-Vail, 2015).
Biological Synergism
The final concept of the syndemic theory is biological synergism. This is
described as the interaction that occurs between two diseases within the body of the
individual. Biological synergism is not the same as a mere comorbidity or coinfection. A
coinfection refers to concurrent diseases without synergistic effects. In order to be
defined as syndemic, the two diseases must result in excess burden when present
concurrently. Some ways in which syndemic diseases interact in the body include
enhanced contagiousness, accelerated virulence, greater expression of symptoms,
physical alterations of the body, and gene assortment between pathogens and iatrogenic
interactions (Douglas-Vail, 2015). An example of this concept is seen in the interaction
between the two viruses HIV and HBV. Research suggests that HIV and HBV may have
physical interactions at the cellular level in coinfected individuals (Ockenga et al., 1997).
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HBV infects the T-lymphocytes, the primary cellular target of HIV, which in turn
contributes to faster HIV replication and a more rapid progression to AIDS.
The full impact of HIV/AIDS stems from its syndemic interaction with various
other diseases. The virus works together with a range of pathogens, such as hepatitis, TB,
malaria, leishmaniasis, herpes and other STDs. HIV/AIDS also interacts unfavorably
with non-infectious diseases and disorders, such as kidney disease, food deficiency,
behavioral health problems, and cardiovascular diseases (Singer 2009). A study by
Pugliese et al. (2002) showed that a syndemic interaction between human papillomavirus
and HIV triggers greater chances of the development of cervical cancer in women when a
coinfection by the two viruses is present. In another study, Pugliese et al. (2002) showed
that when the effect of the coinfection with HIV and human herpesvirus type 8 was
investigated among women, findings suggested that coinfection led to accelerated
deterioration of the immune and hematopoietic systems.
The syndemic theory is a valuable tool in the public health fight against HIV. The
theory is used to understand the connections between diseases by examining routes of
transmission and interrelated health problems which result in excess disease burden
(Singer, 2010). Researchers rely on the syndemic theory to understand the forces that tie
diseases together. It suggests that medicine and public health should shift focus from
individual risk behaviors to relationships, context, and processes (Singer, 2010). One of
the greatest strengths of the syndemic theory is its ability to inform prevention and
treatment programs. The syndemic approach aims to develop a richer understanding of
disease prevention using broad public heath-based initiatives for the creation of programs
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to address and lessen the impact of syndemics currently affecting populations and
programs designed to predict and prevent the emergence of future syndemics. This study
focused on the biological synergism component of the syndemic theory.
Human Immunodeficiency Virus
Originally seen in the 1980s, HIV is the causative agent of AIDS (Sarngadharan
et al., 1984). HIV has an attraction for the body’s T cells. These are the white blood cells
responsible for the cell-mediated immunological response, commonly referred to as CD4
cells. CD4 cells are instrumental in the body’s ability to intervene against disease
acquisition and are required for the proper functioning of the human immune system. The
virus enters these white blood cells via CD4 receptors. The virus then uses mechanisms
in the white blood cell to replicate itself and spread throughout the body, slowly killing
all the infected person’s T cells. Lower CD4 counts mean a higher likelihood of health
issues and sometimes death related to HIV, as the infected person’s immune system no
longer functions to fight off infection. In weakened immune systems, opportunistic
infections that would typically not occur in healthy individuals become great threats.
These infections become easily acquired and difficult to treat. The infections may often
leave an HIV-infected individual severely ill and, if unmanaged, with a high risk of death
(CDC, 2016).
HIV resides in white blood cells that can be found in some body fluids, such as
blood, semen, breast milk, and vaginal fluid. Thus, one of the primary pathways of
acquisition is transmission through sexual intercourse. Other transmission pathways
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include intravenous drug use (IDU), vaginal birth, and breast feeding by HIV-positive
mothers. There is currently no cure or vaccination for HIV.
As of December 2019, an estimated 38.0 million people globally were living with
HIV. 1.7 million became newly infected in 2019, and 690,000 died of an HIV-related
illness (UNAIDS, 2020). Although HIV transmission has declined since 2001, more
people are living with HIV than ever before due to the use of ART (Platt et al., 2015). In
2018, the CDC estimated 37,968 incident cases of HIV in the United States. Of these
cases, 70% were among gay and bisexual men or men who sleep with men (MSM).
African Americans, Hispanics and Caucasians were responsible for 44%, 25% and 28.3%
of the new infections, respectively (CDC, 2020). Adult women with high-risk
heterosexual behavior accounted for 20.0% of the new infections, and men with similar
high-risk heterosexual behavior accounted for only 10.3% of new infections. Other risk
categories included IDU (10.0%) and a category classified as other (0.1%) that included
hemophiliacs, blood transfusion recipients, perinatal exposure, or unknown/unreported
exposure (CDC, 2020).
The age distribution of all HIV cases in 2018 revealed substantial increases in
case numbers beginning at age 20. There were 14,740 new cases of HIV for those
between the ages of 20 and 29 years, and 9,943 for those in the age group between 30 and
39 years. Cases began to decline for those between 40 years and 49 years (6,490 new
cases), and for persons aged 65 years and older with fewer than 2,000 cases (CDC, 2020).
Geographically, the South had the highest incidence rate for HIV in 2018 with 15.6 cases
per 100,000 people (CDC, 2020). In the South, Georgia leads with the highest incident
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rate of HIV diagnosis, 23.8 cases per 100,000. Disparities in HIV are also found in
socioeconomic status, defined in terms of education, income, levels of poverty,
educational attainment, and access to care. Poverty is associated with low educational
attainment, low income, and reduced access to care. Persons with lower income tend to
have lower education, less access to care, and increased HIV incidence (Fenton, 2004). In
the United States, rates of HIV among MSM were still the highest among all subgroups
(CDC, 2020); this likely explains the large amount of research focusing on MSM.
Hepatitis B Virus
Hepatitis B is a liver infection caused by HBV, which is transmitted through
blood, semen, or other bodily fluids through sexual contact; sharing needles, syringes, or
other drug-injection equipment; or from mother to baby at birth. For some people,
hepatitis B is an acute or short-term illness, but for others, it can become a long-term,
chronic infection. Chronic Hepatitis B can lead to serious health issues, like cirrhosis or
liver cancer. The best way to prevent Hepatitis B is by getting vaccinated.
In 2018, an estimated 257 million people are living with HBV. In 2018, a total of
3,322 cases of acute HBV in the Unites States was reported to CDC. As of 2018, CDC
estimated that almost 862,000 persons in the United States had chronic HBV. The
incidence of HBV infection differs significantly by race and ethnicity, with the highest
rates being among Blacks, and rates being higher among Hispanics than non-Hispanics.
Incidence also varies by age, with the highest rates reported among persons 20-39 years
of age. In Georgia, there were 1,421 reported incident cases in 2018. The most common
risk factors reported in Georgia were IDU, multiple sex partners, and MSM.
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Hepatitis C Virus
HCV is an RNA virus that causes acute and chronic liver infection. In the US,
about two- thirds of HCV-infected people become chronic carriers, while the remaining
one-third may spontaneously clear the virus without requiring any treatment. HCV
infection is the most common chronic blood-borne infection in the United States. In
2005, more than 184 million people were estimated to have been infected with HCV. By
2014, this number had declined to 115 million as a result of improved screening of blood
donations and decreased IDU (Platt et al., 2016).
Chronic HCV infection is a major cause of mortality and morbidity across
countries. There are an estimated 177 million people infected worldwide (Petruzziello et
al., 2016). An estimated 2.7-3.9 million people in the United States have chronic
hepatitis C. HCV infection occurs among persons of all ages, but the highest incidence of
acute Hepatitis C is found among persons 20-39 years. African Americans and Whites
have similar incidence rates of acute disease, with higher rates in persons of Hispanic
ethnicity. In Georgia, there were 5,451 reported incident cases in 2018. The most
common risk factors reported were IDU, multiple sex partners and MSM.
HIV/HBV Coinfection
The viral diseases of hepatitis and HIV/AIDS are known as the twin epidemics,
due to their similarities and consequences of coinfection (Highleyman, 2003). A growing
body of literature indicates that HIV positive individuals are more likely to be infected
with HBV than HIV negative individuals, possibly as a result of shared risk factors
(Mallet et al., 2011). There is also evidence that HIV positive individuals who are
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subsequently infected with HBV are more likely to become HBV chronic carriers and
have a high HBV replication rate. In addition, it is evident that immunosuppression
brought about by HIV infection may cause reactivation or re-infection in those previously
exposed to HBV. Furthermore, HIV infection exacerbates liver disease in HBV
coinfected individuals, and there is an even greater risk of liver disease when HIV and
HBV co-infected patients are treated with ART. Complicating matters further, there have
been several reports linking HIV infection to "sero-silent" HBV infections, which present
serious problems for diagnosis, prevention, and control (Platt et al., 2015) (MarineBarjoan et al., 2014).
There are several studies that suggest that HIV immunosuppression may reduce
liver damage as a result of a less aggressive HBV specific immune response, and this is
supported by reports of a reduction in icteric illness in acute HBV infections in HIV
positive patients (Highleyman, 2003). However, HIV infection has been found to
exacerbate liver disease, with an early study finding death from liver failure in four of
five HIV/HBV coinfected individuals compared with two of six HIV negative HBV
infected individuals (Matthews et al., 2014).
HIV/HCV Coinfection
Of special concern regarding HIV coinfection is the HCV. Both HIV and HCV
are rapidly replicating RNA viruses, and both are transmitted via blood contact. A
common route of transmission is multiple sharing syringes by injection drug users
(Singer et al., 2000). The prevalence of HCV in HIV-infected populations is highest in
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IDU, followed by MSM and pregnant or heterosexually exposed populations (Platt et al.,
2015).
Many studies suggest that HIV infection leads to hepatitis infections that are more
aggressive than those in individuals not infected with HIV (Singer, 2009). The interaction
between HIV and HCV in coinfection affects the transmission and natural history of the
HCV infection. HCV transmission proficiency increases in the presence of the HIV
infection (Platt et al., 2015). People living with HIV who do not receive ART have
reduced chances of naturally clearing the HCV infection, have increased HCV VLs, and
experience more rapid HCV disease progression than those without HIV infection (Platt
et al., 2015). In HIV/HCV coinfected individuals, successful ART leading to viral
suppression of HIV replication is associated not only with lower rates of AIDS-related
disorders but also with slower progression of liver fibrosis and lower mortality from liver
disease (Marine-Barjoan et al., 2014).
In contrast to HIV negative individuals, HIV positive individuals infected with HCV
usually become chronic carriers (Thomas et al., 2000). Among those infected with HCV,

approximately 20–45% spontaneously clear the infection without treatment; this
proportion is lower in HIV coinfected individuals due to weaker HCV specific immune
responses (Moqueet et al., 2015). Although ART has been found to improve HCV
outcomes in coinfected patients, the HCV coinfection may complicate HIV treatment.
Evidence have suggested an increased risk of drug related hepatoxicity in those receiving
ART for HIV infection (Taylor et al., 2012). Such negative outcomes appear to be as a
result of the inability of the immune system to contain HCV when under attack from
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HIV. Even in cases where it seems that the body has been able to clear HCV, as the
immune system deteriorates, HCV replication restarts (Kim et al., 2006).
The question of the impact of HCV on the natural history of HIV disease remains
of considerable interest. Prior to the availability of combination ART (pre-1996),
increased rates of HIV disease progression largely masked any effects of HCV disease on
HIV. Since then, Greub et al. (2014), reported from the Swiss Cohort Study that HCV
infection was associated with a 70% increased probability of progression to a new AIDS
defining event or death. Some studies have confirmed his findings, such as Bonacini et al.
(2004), which found that the hepatitis viruses do in fact have potential associations with
poor HIV outcomes, while other studies refute these findings (Kim et al., 2006).
There are many ways that HCV could impact HIV disease progression; for
example, liver disease may preclude the use of ART because of hepatotoxicity. Many
coinfected individuals, because of sociodemographics or uncontrolled addiction, simply
never access ART and die of AIDS. It is also possible that HCV has a direct influence on
HIV infection, although the mechanism of action is yet unknown. As people with HIV
live longer, HCV related liver disease in coinfected patients is becoming a major cause of
morbidity and mortality. However, the burden of HIV/HCV coinfection is poorly
understood.
HIV and Viral Suppression
Viral suppression is a measure that indicates a progression along the HIV care
continuum. When a person living with HIV begins an ART regimen, his/her HIV VL
decreases. For almost everyone who takes his/her HIV medication daily as prescribed, the
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HIV VL will decrease to an undetectable level in six months or less. A person’s HIV VL
is considered undetectable when all VL test results are undetectable for at least six
months after the first undetectable test result. Continuing to take HIV medications as
directed is imperative for the HIV VL to remain undetectable. Persons living with HIV
who take antiretroviral medications daily as prescribed and who achieve and then
maintain an undetectable VL, have effectively no risk of sexually transmitting the virus to
an HIV negative partner. According to recent data, of the estimated 1.2 million people
infected with HIV in the United States, almost 210,000 are virally suppressed (Gardner et
al., 2011).
Persons with high initial CD4 counts have a greater likelihood of reaching HIV
viral suppression (Yehia et al., 2014). The CD4 cell count is important, because it allows
clinicians to monitor how well a person’s body is responding to ART and it provides an
overall status of the persons’s immune system (Brenan et al., 2013). The CD4 cell count
is used clinically in determining how quickly ART needs to be initiated and when to start
and discontinue prophylaxis for opportunistic infections and is a predictor of disease
progression and survival (DHHS Panel on Antiretroviral Guidelines for Adults and
Adolescents, 2015). CD4 cell count is also used to monitor ongoing disease progression
and severity and to determine stage of HIV infection (Stage 1 is a CD4 count of greater
than or equal to 500 cells/μL or a CD4 percentage of total lymphocytes of greater than
26, Stage 2 is a CD4 count of 200- 499 or CD4 percentage of total lymphocytes of 14 –
25, and Stage 3 is a CD4 count of less than 200 or CD4 percentage of total lymphocytes
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of less than 14 (Selik et al., 2014). CD4 cell count is a strong predictor of death but is
modified by HIV viral suppression and time on ART (Brennan et al., 2013).
Literature Related to the Content
Several studies have investigated the health outcomes of an HIV coinfection with
HBV or HCV; however, to date, very few have researched the effects of the CD4 cell
count on the coinfection. The data in this area, most published over a decade ago and in
both the pre-combination and post-combination ART eras, are mixed in their findings,
largely using endpoints of AIDS defining events or death.
A search of the literature showed that there are conflicting reports on the effect of
HBV/HCV infection on the natural history of HIV disease. The Swiss HIV Cohort Study
for example found that in the first year of initiating ART, HCV infected individuals had
smaller increases in CD4 cell counts than HCV negative individuals (Kaufmann et al.,
2003). The EUROSIDA study did not find an effect of HCV on HIV disease progression,
but there was an increased risk of liver-related deaths among HCV coinfected individuals
(Rockstroh et al., 2005).
In Piroth et al. (1998) longitudinal study, immunologic progression was examined
in HIV/HCV coinfected persons. One hundred and nineteen HIV infected persons
coinfected with HCV, and 119 matched individuals infected with only HIV were
included in the cohort. Clinical progression was defined as one or more of the following:
a 20% loss of body weight; an AIDS-defining illness (for non-AIDS patients); and/or
death (except by accident, suicide or overdose). Immunological progression was defined
as a 50% decrease in the initial CD4 T-cell count (for patients with an initial count > 100
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x 10(6) cells/l). Effects of HCV coinfection were evaluated using Kaplan-Meier survival
analysis, and significance was tested using univariate (log-rank and Peto's tests) and
multivariate methods (Cox regression). Clinical progression was more rapid in HIV/HCV
coinfected patients than in HIV positive patients not infected by HCV in that CD4 cell
counts of more than 600mL declined when HCV was present. This might suggest a
greater impact of HCV on HIV disease progression in early HIV infection.
Greub et al. (2014) found that after effective ART, HIV/HCV patients had a
modest increased risk of progression to a new AIDS defined illness or death. In this
study, 1157 patients (37.2%) were coinfected with HCV. In multivariate Cox regression,
the probability of progression to a new AIDS-defining clinical event or to death was
independently associated with HCV infection (hazard ratio 1.7 [95% CI 1.26-2.30]).
HCV infection was associated with a smaller CD4 cell recovery (hazard ratio for a CD4cell count increase of at least 50 cells/microL=0.79 [0.72-0.87]).
In a study by Sarkar et al., (2016), 1331 confirmed HIV positive individuals were
initiated on ART. Among the participants, 1253 were only infected by HIV, and 78 were
HIV/HBV coinfected. All participants, before starting ART, were subjected to baseline
mandatory laboratory testing [CD4 count, complete hemogram, liver function tests
(LFT), fasting blood sugar, blood urea, serum creatinine, venereal disease research
laboratory (VDRL), hepatitis B surface antigen (HBsAg), routine stool and urine analysis
and chest X-ray [posterior anterior (PA) view]. HIV/HBV coinfected individuals had
more advanced HIV disease (WHO clinical stage 3 and 4) than HIV- only infected
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individuals (37.1% vs. 19.9%). CD4 cell count was non-significantly lower in coinfected
patients.
A study done by Bani-Sadr et al. (2014), examined the impact of HCV-related
characteristics such as genotype, VL or liver fibrosis on the chances of achieving
sustained HIV suppression in coinfected patients. Eight hundred ninety-seven patients
were examined to determine the relationship between HIV/HCV-related and social
behavioral characteristics and HIV sustained viral suppression (SVS). The main outcome
variable was HIV SVS, defined as at least two consecutive undetectable HIV VLs.
Among the 897 HIV/HCV coinfected patients, 419 (47%) had received HCV therapy at
least once, and 103 patients (25%) had experienced an HCV sustained virologic response
(SVR). Results showed that HCV SVR was associated with a higher likelihood of
achieving HIV SVS.
Van Santen et al. (2019) aimed to assess the effect of incident HCV infection and
its timing relative to HIV seroconversion in HIV positive MSM on their subsequent CD4
cell count and HIV VL. HCV/HIV coinfected MSM were matched to HIV only infected
MSM by time of HIV infection and combination ART use. Two-hundred fourteen HIV
infected and 147 HCV/HIV coinfected MSM were matched to 3954 controls, HIV only
infected MSM. The timing of HCV seroconversion relative to HIV seroconversion had
no evident effect on HIV VL or CD4 cell count. In the first 2-3 years following HCV
infection, CD4 cell counts were lower among HCV/HIV coinfected MSM but became
similar to counts in HIV only MSM years later. The authors concluded that regardless of
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the duration of HIV infection when HCV is acquired, CD4 cell counts are temporarily
lower following HCV, even when on ART.
In a study done by Aibibula et al. (2018), the association between poor HIV viral
control and immune recovery among person coinfected with HCV/HIV was examined. A
total of 725 participants was enrolled between 2012 and 2015. At baseline, 52% of the
participants reported having depressive symptoms, and 75% had an undetectable HIV VL
(HIV virally suppressed). Participants experiencing depressive symptoms had 1.32 times
(95% CI: 1.07, 1.63) the risk of having detectable HIV VL (not HIV virally suppressed)
but had comparable CD4 count to people who did not experience depressive symptoms.
The presence of depressive symptoms was thus a risk factor for incomplete, short-term,
HIV viral suppression among people co/infected with HIV/HCV.
Aibibula et al. (2018) also examined the impact of food insecurity on HIV viral
VL and CD4 cell count among people coinfected with HIV and HCV. There were 725
HIV/HCV coinfected people with 1973 person-visits over 3 years of follow-up in the
study. At baseline, 23% of participants experienced moderate food insecurity, and 34%
experienced severe food insecurity. The proportion of participants with undetectable HIV
viral load was 75%, and the median CD4 count was 460 cells/μL. Participants
experiencing severe food insecurity had 1.47 times the risk of having detectable HIV
viral load compared with people who were food secure. These findings provide evidence
of the negative impact of food insecurity on HIV viral load and CD4 cell count among
HIV/HCV coinfected people.
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Cescon et al. (2014) compared HIV treatment outcomes and survival between
HIV/HCV coinfected individuals with and without IDU history. This study was restricted
to 1254 participants with HIV/HCV coinfection and known IDU history. During a
median follow-up time of 3.8 years, 217 deaths were reported. In adjusted multivariable
analysis, individuals with IDU history were significantly less likely to achieve virologic
suppression and CD4 cell count recovery and had a significantly higher risk of mortality.
Despite the adverse clinical consequences of HIV/hepatitis coinfection, the
mechanisms by which these two viruses interact at the cellular level remain largely
unexplored. At present, the literature suggests that the major contribution of hepatitis to
coinfected individuals is accelerated liver disease and increased HIV/AIDS-related
complications. A better understanding of the interactions between these two viruses is
vital to the development of novel treatment strategies to control HIV/hepatitis
coinfections.
Literature Related to Methods
Epidemiological studies may be experimental, quasi-experimental, or
observational. Both experimental and quasi-experimental involve manipulation of a study
factor, while an observational study observes naturally occurring phenomena to make
inferences (Friis & Sellars, 2004,). Research methodologies include qualitative,
quantitative and mixed methods. Among the quantitative studies reviewed were
retrospective studies, cohort studies, and cross-sectional studies (Rao et al., 1998; Stekler
et al., 2005; Shah et al., 2002). Like the proposed research, some of the studies
retrospectively examined medical records and charts. An advantage to a medical record

30
review is that the data are already present and do not have to be collected by the
researcher.
In a case-control study in African American women, the researchers evaluated
social, behavioral, and epidemiologic risk factors which potentially predispose a person
to HIV (Forna et al., 2006). Focus groups were used to gather information regarding HIV
behavioral risk factors and recommendations to minimize transmission among African
American women. The case-control study design allowed the researcher to evaluate risk
factor data as well as presented topics for future investigation as described by the
participants.
In a case-control study conducted by Resino et al. (2014), phenotypic and
functional parameters of immune restoration were evaluated in 27 HIV-infected patients
on HAART. The patients were compared to 11 HIV infected controls that never had less
than 500 CD4 cell counts. The participants were followed for 18 months. Results showed
that the cases (HAART patients) with a previous state of severe-moderate
immunosuppression normalizing their CD4 cells had an incomplete immune
reconstruction after HAART.
Skiest et al. (2006), used a case-control methodology to study the impact of
comorbidity on the course of HIV disease in older patients as compared to a matched
cohort of younger patients. Forty-three HIV infected patients, 55 years and older, were
compared to a randomly selected group of 86 patients 45 years old, matched by date of
HIV diagnosis. Data were collected on non-HIV-related morbidity, initiator of HIV
testing, HIV stage at time of HIV diagnosis (TOHD), AIDS defining diagnoses, AIDS-
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related illnesses (ARI), observed AIDS-free interval, survival, and frequency of HIVrelated and unrelated hospitalizations. Results showed that older HIV infected patients
presented with more advanced disease, which may have been due to lack of HIV
awareness in this population, had a shorter survival and had more HIV- and non-HIVrelated comorbidity than the younger patients. The more rapid course and decreased
survival in the elderly may have been related to possible comorbidity confounders.
Lawrence et al. (2001), performed a case-control study to investigate the impact
of early untreated HIV infection on chronic HCV. Medical records were examined for
HIV-infected patients who had a medical exam during 1995-1996. Patients were screened
for IDU, CD4 cell count, ART, and positive anti-HCV antibody. Thirty-eight eligible
HIV-infected patients (cases) and 38 HCV infected patients without HIV (controls) were
randomly matched by age, sex and duration of HCV infection. The study found that early
treated HIV infection is associated with higher HCV viremia and more severe liver injury
in IDUs with chronic HCV.
Ying Yu et al. (2018), used a case-control study to examine the HCV viral loads
among IDUs with HCV infection, HCV/HIV coinfection, and HIV/HBV coinfection.
Among the 45 IDUs recruited, 27 were HCV mono-infected, 9 were HCV/HIV
coinfected; 7 were HCV‐HBV coinfected, and 2 were seronegative for HCV, HBV, and
HIV infection. A control group of 180 age and gender matched chronic HCV infected
non IDU patients was enrolled. Results showed that the HCV RNA levels in IDUs with
HCV/HIV coinfection were significantly higher than those in the control group, the
IDUs with HCV only infection group, and IDUs with HIV/HBV coinfection group (P <
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0.001, P < 0.001, and P < 0.001, respectively). IDUs with HCV/HIV coinfection suffered
worse outcomes. Programs for how to block HIV transmission in this group need to focus
on the education and routine check- ups of those with risky sexual customs and practices.
A case-control study by Darraj et al. (2018), was performed to characterize the
factors associated with decreased immunological response among Manitoba's HIV
population. The case-control study included HIV patients with immune reconstitution
failure despite suppression of HIV replication by ART. Immune reconstitution failure
was defined by CD4 cell count increase from baseline of less than 100 CD4 cells/mm or
lack of increase to above 200 CD4 cells/mm within one year of viral suppression. A total
of 42 individuals who met the definition of immune reconstitution failure were assigned
as cases. Controls were 31 patients comprising a range of ages and CD4 cell counts like
those of the cases. Results showed that age and a low CD4 cell count before the start of
ART were possible predictors of immune reconstruction failure.
Advanced HIV infection despite sustained viral suppression by HAART is a risk
factor for poor immunologic recovery. However, some patients with advanced infection
do recover. Kim et al. (2015), examined predictive factors of immunologic recovery in
advanced HIV patients showing sustained viral suppression. A case-control study was
conducted in HIV-infected adult patients with an HIV diagnosis of 4 years or longer who
were receiving HAART. Advanced HIV infection was defined as a baseline CD4 T cell
count < 200/mm or AIDS. Immunologic responders were defined as patients showing
immunologic recovery (CD4 cell counts ≥ 500/mm at 4 years with HAART). Of 102
eligible patients, 73 had advanced HIV, and 33 showed immunologic recovery. The

33
median CD4 slopes during 0 to 6 and 0 to 12 months of HAART in the advanced patients
were significantly higher in responders than in non-responders. Multivariate analyses
showed opportunistic infections at the start of HAART were independently associated
with immunologic recovery. Coinfection with HCV and HBV were among the factors
that were associated with a poor immunologic response.
Brites-Alves et al. (2015), also used case-control methodology to compare virally
suppressed HIV patients according to restoration pattern: adequate response (AR), partial
response (PR), and inadequate response (IR). A total of 293 patients, 92 cases and 189
controls, (89 AR, 112 PR, and 92 IR) were evaluated. A previous diagnosis of HCV or
Tb was associated with IR. Longer time on ART was associated with a greater chance of
AR, but logistic regression identified coinfection by HCV as the main factor associated
with abnormal CD4 ratio. They concluded that previous HCV diagnosis significantly
increases the risk of abnormal CD4 cell count.
Summary
In the United States, there are between 2.2 and 4.7 million people infected with
viral hepatitis (HHS, 2020). Persons living with HIV/AIDS (PLWHA), are among those
populations who are disproportionally affected by viral hepatitis (HHS, 2013). HCV and
HBV, due to their high prevalence in them, are among the leading causes of morbidity
and mortality in the HIV positive populations (Matthews et al., 2014). The literature has
revealed that HIV infection leads to hepatitis infections that are more aggressive than
those in individuals not infected with HIV, but a focus on the effects of HBV/HCV on
HIV viral suppression and CD4 cell counts has not been fully researched. HIV viral
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suppression is the goal of ART. People living with HIV who achieve and maintain an
undetectable VL have effectively no risk of sexually transmitting the virus to an HIV
negative partner. Given that HBV and HCV are heavily prevalent in the HIV population,
it is essential to understand if a coinfection by either of these viruses effects the
achievement of HIV viral suppression and leads to decreased CD4 cell counts.

35
Chapter 3: Research Method
Introduction
In this chapter, I describe the research methodology used for this study. The goal
of this chapter was to give a description of the study design and secondary data sources.
This chapter also includes the data collection procedure and the data analysis plan. This
chapter concludes with a summary of the research methods used.
Research Design & Approach
An observational approach was used as opposed to an experimental approach, as
variable manipulation in the latter would be both illogical and unethical. The study
sample included those with reported HIV and/or hepatitis data available in the GDPH
eHARS and SENDSS databases between 2012 and 2016.
The case-control design methodology was used for this study. The case-control
methodology allowed me to compare the HIV CD4s and viral loads of persons coinfected
with HIV and HBV or HCV with those who are only infected with HIV. The exposure
variable of interest and will have three categories: HIV only infection, HIV/HCV
infection, and HIV/HBV infection. The outcome variables of interest were HIV viral load
suppression and CD4 cell count. After data collection all exposure variables, HIV only,
HIV/HCV, and HIV/HBV were evaluated for CD4 cell counts and HIV viral loads.
Population and Sample
The study sample was drawn from reports in the state of Georgia that were
reported positive for the HIV infection with and without HBV or HCV between the years
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2012 and 2016. The sample only contained persons aged 18 years and older living in
Georgia at the time of a positive diagnosis or diagnoses.
This study used quantitative measures. According to Polit and Beck (2012),
quantitative research designs often require large samples to increase representativeness
and reduce sampling error. The sample size is chosen to maximize the chance of
uncovering a specific mean difference that is statistically significant (Polit & Beck,
2012).
Research data collected in public health practice can be primary or secondary
(Struwig and Stead, 2001). Secondary data were used for this study.
The study population was drawn from notifiable disease reports received by the
GDPH SENDSS and eHARS. Individuals reported to be diagnosed with HBV or HCV
between the years of 2012 and 2016 was extracted from the SENDSS database and
matched with prevalent HIV cases in eHARS, a database used to collect information on
individuals infected with HIV/AIDS.
Based on the G*Power analysis program using the chi-square statistic with a
medium effect size of w= 0.30 and an alpha of 0.05, the needed sample size was 94; for a
small effect size of w= 0.01, the needed sample size would have been 840; and for a large
effect size of w = .50, the needed sample size would have been 34.
Data Collection
The state code grants the GDPH general authority to use surveillance data to
investigate preventable disease in the state of Georgia. It also permits the GDPH to
collect personal information and health data for the purpose of surveillance that may
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prevent and control disease, and it protects the GDPH from civil liability when the data
are used as required by law for surveillance. Georgia law allows the GDPH to review and
collect the medical records of any medical facility in Georgia for the purpose of disease
investigation.
Access to the data for this study was provided by the GDPH. Permission to use
the data was granted by the Office of Science, Research, and Academic Affairs in DPH.
Upon IRB approval from GDPH and Walden University, the HIV data manager at the
GDPH performed an HIV and hepatitis case match between SENDSS and eHARS for the
population of coinfected cases. The cases were matched by last name, first name and date
of birth. The resulting de-identified dataset of the match was provided for this study.
The data were presented as a SAS dataset, which included requested variables, and were
transferred securely to the researcher using a password-protected jump drive and were
stored in a locked safe at GDPH when not in use.
The request for HBV, HCV, and HIV data collected through December 2016 was
submitted to the Georgia DPH in December of 2019. Year-end data of 2016 were the
most complete CDC approved data for Georgia at the time of the request. The data
request was approved by the GDPH in February 2020, and the data were received from
the DPH data submission portal in March 2020. Due to Georgia laws for the protection of
human subjects, race/ethnicity data were grouped as White, Black, and other, further deidentifying the data. The dataset was cleaned by deleting all duplicates as well as
unknowns such as in gender and race.
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Measures and Variables
The information used to create the data set was gathered from disease case
reports, field records, laboratory reports, and interview records. The last four most recent
VL counts for the all sample participants were also included in the database for
assessment of HIV viral suppression. A review of CD4 cell counts was used to
understand if viral hepatitis impedes the achievement of HIV viral suppression, which is
defined by the HIV care continuum and CDC as the most recent VL count less than 200
copies/mL. The care continuum is important in HIV/AIDS data because it allows for
CDC and other public health agencies to monitor how the United States is doing
regarding all persons living with HIV, monitor disparities by examining data among subgroups of the population, and monitor data at the local level to understand local progress
and identify additional action steps to meet national level goals. In this study, the care
continuum definition of viral suppression, was used as a measure to evaluate if HIV is
affected by HBV or HCV.
Data Analysis
Univariate and bivariate analyses were conducted for this study. For all bivariate
analyses, an alpha value of 0.05 was used to determine whether the observed outcome for
the specified variables differed significantly from the expected outcome. All statistical
analyses were carried out using SAS version 9.3.
External Validity
The main threat to the external validity of this study may be the sample being
used from a specific location within the US, so the data may only be applicable to
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Georgia. The sample will be derived from data reported to the GDPH. Since some
persons with disease have not been diagnosed or reported, they will not be present in the
data set.
Internal Validity
Possible threats to the internal validity of this study may be the presence of
confounders, such as other health related outcomes that may or may not influence HIV
viral suppression, such as other STIs or chronic health conditions. Unfortunately,
databases which may contain this information are not easily accessible or linked at
GDPH, but I do not foresee any major threats to the results of this study because of this
issue.
Ethical Protection of Participants
The study proposal was submitted to the Walden GDPH IRB and Walden
University IRB for review and approval to ensure the adherence to ethical standards and
federal regulations. Additionally, the GDPH required completion of a data request form
which also consists of a data use agreement. Identifiers in the data received from GDPH
were removed by the agency prior to its releasing. This decreased the likelihood of
having a leak of private health information, which would violate HIPPA regulations.
Upon completion of the project, the GDPH mandated the return or destruction, by a
predetermined method, of all data. These steps ensured the ethical treatment of all
participants.
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Summary
Observational research was used to determine whether a coinfection with HBV or
HCV inhibits HIV viral suppression in an HIV infected individual. All exposure variables
will be evaluated for CD4 cell counts and HIV viral loads. The sample included persons
18 years or older who were reported and diagnosed with either HIV, HBV or HCV while
living in Georgia. The dataset was created by GDPH and given to the researcher after
approval of both DPH and Walden University’s IRB. Data analysis were performed using
SAS to test the null hypotheses and their associated alternative hypotheses.
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Chapter 4: Results
Introduction
This chapter provides the results of a case control study using the data from the
GDPH on HIV, HBV, and HCV disease reports through the year ending 2016. The
research questions examines the associations between a coinfection with viral hepatitis
and HIV viral load suppression in HIV positive individuals and assesses the impact of
HBV and HCV on CD4 counts in HIV patients. This chapter provides an overview of the
demographic, HIV viral suppression, and CD4 characteristics of the study sample,
reviews the research questions and hypotheses, reports the statistical analyses, and
summarizes the study findings.
Demographic Characteristics and Results of Bivariate Analysis
The study sample included a combined total of 65,626 reports of HIV/HBV (n=
2,034), HIV/HCV (n= 3,321), and HIV only infected (n= 60, 271). The population
consisted of 76.3% males and 23.4% females. Age was stratified into five categories:
10.3% were between the ages of 20 years and 29 years; 22% were between the ages of 30
years and 39 years; 22.1% were between the ages of 40 years and 49 years; 28.1% were
between the ages of 50 years and 59 years; and 17.5% were aged 60 years and older.
Regarding race/ethnicity, 68% of the study population were non-Hispanic African
American, 18% were non-Hispanic White, and 14% were defined as Other. The
demographic characteristics for each category of the exposure variables (HIV/HBV,
HIV/HCV, HIV only) are presented below (Table1).
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Table 1
Demographic Characteristics by Disease Status
HIV/HBV

HIV/HCV

HIV only

Gender
Males
Females

1,778
236

2,570
723

45,203
14,381

Race
White
Black
Other

360
1,437
237

609
2,302
3,321

10,861
44,591
8,558

66
360
597
690
314

138
456
574
1,109
1,041

6,563
13,512
13,313
16,610
10,071

Age (yrs)
20-29
30-39
40-49
50-59
≥60

Risk factor
*MSM
1486
1654
36,916
*IDU
96
627
3,550
Note. N=65,626 *MSM=Men who have sex with men *IDU= Intravenous drug user

Research Questions and Hypotheses Testing
To answer the research questions, each hypothesis was tested to assess the
potential associations between the exposure variable and outcome variables. For each of
the hypotheses, a Pearson Chi-square analysis and measure of associations are presented
below.
RQ1: Is there an association between coinfection with viral hepatitis and HIV
viral load suppression in HIV positive individuals?
Ho1: There is no association between coinfection with viral hepatitis and HIV
viral load suppression in HIV positive individuals.
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Ha1: There is an association between coinfection with viral hepatitis and HIV
viral load suppression in HIV positive individuals.
Results suggest that people with coinfection (HIV/HBV and HIV/HCV) had more
HIV viral suppression than those who were only infected with HIV (Figure 1).
Individuals who were coinfected with HIV and HBV were more likely to have achieved
HIV viral load suppression than individuals who were only infected with HIV (OR=1.45,
95% CI 1.32-1.59, p= .0001). A similar observation was seen for individuals who were
coinfected with HIV and HCV (OR= 1.55 95% CI 1.44-1.67, p= .0001). Therefore, I
rejected the null hypotheses which stated that there is no association between coinfection
with viral hepatitis and decreased HIV viral load suppression in HIV positive individuals.
70
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64
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56
54
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HIV Viral Load Suppression
HIV/HBV

HIV/HCV

Figure 1. HIV viral load suppression by disease status.

HIV Only
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RQ2: Does the type of viral hepatitis (HBV or HCV) impact the CD4 count of the
HIV infection?
Ho2: The type of viral hepatitis (HBV or HCV) does not impact the CD4 count of
the HIV infection.
Ha2: The type of viral hepatitis (HBV or HCV) impacts the CD4 count of the HIV
infection.
HIV/HBV occurrences and HIV/HCV occurrences were evaluated to determine
the impact of HBV and HCV on HIV CD4 cell count. HIV CD4 cell count was measured
based off the AIDS defining definition, a CD4 cell count which drops below 200
cells/mL. When the three categories HIV/HBV, HIV/HCV & HIV only were compared,
the percentage of AIDS defining occurrences, as of year-end December 2016, was greater
in individuals coinfected with HIV/HBV and HIV/HCV than those only infected with
HIV (Figure 2).
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Figure 2. AIDS defining diagnoses by disease status year-end December 2016.

When the CD4 cell counts of HIV/HBV coinfected individuals were compared to
the CD4 cell counts of HIV/HCV coinfected individuals using the HIV care continuum
time points (3 months after HIV diagnosis, 12 months after HIV diagnosis, and current
year-end), there was a significant difference in the amount of AIDS defining cases. At all
time frames, HIV/HBV coinfected individuals were more likely to have low CD4 cell
counts, (AIDS defining), than HIV/HCV coinfected individuals (Table 2). Therefore, the
H02 null hypothesis which states that the type of viral hepatitis (HBV or HCV) does not
impact the CD4 cell count of the HIV infection is rejected.
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Table 2
AIDS Defining at Care Continuum Time Points
AIDS (%)
3 Months
χ2= 24.8

HIV/HBV

HIV/HCV

OR (95% CI)

20.63

15.32

*1.44(1.23,1.74)

12 Months
χ2= 31.1

24.01

17.72

*1.47(1.31,1.71)

Year-end December 2016
χ2= 39.1

68.71

60.31

*1.45(1.34,1.67)

Note. * p < .001
Summary
The study findings were presented in this chapter. This included a demographic
summary of the study population. Both research questions were assessed to determine the
variables significantly associated with HIV viral load suppression and HIV CD4 cell
counts. In research question one, a coinfection with HBV and HCV was determined to be
associated with HIV viral load suppression when compared to individuals only infected
with HIV. In research question two, a coinfection with HBV was found to have a greater
impact on CD4 cell counts in all time frames of the HIV care continuum than a
coinfection with HCV in individuals infected with HIV. Chapter 5 provides a discussion
of the findings, limitations of the study, recommendations for future research, as well as
implications for social change.
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Chapter 5: Discussion, Conclusions, and Recommendations
Introduction
This study had two major purposes. The first was to assess whether an infection
with viral hepatitis B or C hinders HIV viral suppression when present concurrently in
individuals. The second was to assess which hepatitis type (HBV or HCV) had a greater
impact CD4 cell counts in an HIV infected individual. In this chapter, I describe the
results of the study to demonstrate that the purpose was achieved. Chapter 5 includes a
discussion of the study findings, recommendations for further, and the conclusion to this
study.
Discussion and Interpretation of Findings
A significant finding of this study was that persons who were either coinfected
with HBV (OR= 1.45) or HCV (OR=1.55) were more likely to be HIV virally suppressed
than those persons who were only infected with HIV. In a study which looked at the
relationship of HIV viral load suppression and infection with HCV, persons coinfected
with HCV/HIV were two times more likely to have achieved HIV viral load suppression
than persons who were only infected with HIV, considering good adherence to HIV
treatment (OR= 2.05, 95% CI 1.23-3.43, p= 0.006; Bani-Sadr et al., 2014). Good
adherence to HIV treatment, ART, is essential in the HIV infection in that it suppresses
the HIV viral load, restore or preserve immunologic function, and improves the infected
person’s quality of life by reducing the risk of HIV-related morbidity and mortality. The
results of this study could be explained by a greater adherence to ART in the HBV and
HCV coinfected population. Because persons coinfected with viral hepatitis and HIV are
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more likely to have unfavorable health outcomes than persons infected with HIV only,
they may be more likely to adhere to HIV therapy guidance due to the presence of more
than one infection.
In the current study, persons who were coinfected with HBV (OR= 2.12) or HCV
(OR= 1.46) were significantly more likely to have a CD4 cell count below 200cells/ml,
AIDS defining, than persons who were infected with HIV only. AIDS defining cases
were found in 66.6% of persons coinfected with HIV/HBV, 58.5 % of persons coinfected
with HIV/HCV, and 50.5% of persons only infected with HIV. This finding is consistent
with those of several studies (Salmon-Ceron et al., (2005); Sherman et al., (2002); Rana
et al., 2019). As mentioned, HIV is defined as AIDS when an individual’s CD4 cell count
drops below 200 cells/ml at any time during the HIV infection. Piroth et al., (1998), Grub
et al., (2014), and Van Santen et al., (2019) evaluated the progression of AIDS in persons
coinfected with HBV or HCV and observed a decrease in CD4 cells by at least 60% in
coinfected persons in compared to persons only infected with HIV. The current study
finding may indicate that HBV and HCV negatively impact the HIV infection when
concurrently present. This could also explain why persons coinfected with HIV/HBV or
HIV/HCV are more likely to be HIV virally suppressed than those infected with HIV
only. Persons who are defined as an AIDS case may be more likely to adhere to ART
guidance due to the severity of their HIV infection. Without proper treatment adherence,
persons diagnosed with AIDS typically have a survival time frame of 3 years.
Those who were HBV/HIV coinfected were significantly more likely to be AIDS
defining at all time points of the HIV care continuum than HCV/HIV coinfections. This

49
could be a result of the high prevalence of men who have sex with men (MSM) among
those who are infected with HIV. The proportion of MSM who have HIV is higher than
any other group in the US. In 2016, more than half of the HIV infected population
identified as being MSM (CDC, 2020). Since HBV is a common coinfection with HIV,
MSM are disproportionately affected by HBV, with 15-25% of new infections occurring
in this group (Falade-Nwulia et al., 2015). Eskild et al. (2012) looked at the previous and
current HBV infection in HIV disease progression and found that the presence of HBV
antibodies was associated with more rapid HIV disease progression. MSM who were
HBV/HIV infected had a three-time risk of progression to AIDS compared to the
individuals who were only infected with HIV. Also, like the current study, Japhet et al.
(2016), which investigated HIV viral loads in the presence of HBV, found that although
HBV/HIV persons had adequate viral suppression rates, the HBV coinfection was
associated with increased progression to AIDS.
Support for the Theoretical Framework
The results of this study indicated that HBV and HCV do not hinder HIV viral
load suppression in persons infected with HIV, but the two viruses are associated with
more rapid progression to AIDS when a person is concurrently infected with HIV. This
finding is important because it highlights how HBV and HCV can cause excess morbidity
and mortality in persons infected with HIV. In the syndemic theory, the concept
syndemic refers to the tendency for multiple epidemics to co-occur and interact with each
other and worsen the others’ effects (Singer, 2009). The syndemic theory is a valuable
tool in the public health fight against HIV. The theory reveals how important focused
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prevention and control measures are for each disease that plays a role in the syndemic as
well as the prevention and control of the mechanisms that bring the two diseases together.
The current study provided evidence of the excess burden that HBV and HCV
may cause when present with HIV. Given this evidence, there should be more efforts
towards the creation of public health initiatives to address and lessen the impact of HBV
and HCV in HIV infected individuals.
Limitations
The dataset included information from two databases, SENDSS (HBV and HCV
diagnoses) and eHARS (for HIV diagnoses). The two databases contain information on
all persons in Georgia who were tested and diagnosed with either HIV or HBV or HCV.
While both hepatitis and HIV are reportable diseases under Georgia law, there was no
way to guarantee that the data from diagnoses utilizing private insurance and diagnosed
with HIV and/or hepatitis had been captured, so they could potentially have been missing
from the databases. Additionally, people who were positive for HIV and/or hepatitis but
had never been tested were not represented in the dataset. While frequencies of
underreporting of HIV and hepatitis diagnoses in Georgia were not available, the GDPH
did acknowledge that underreporting may be a limitation of the data available in their
databases.
Another limitation included the incompleteness of data on Georgia’s HIV reports.
When diagnoses are reported by providers, often information regarding gender, risk
factors, as well as whether the individual is on ART is missing from the report. This
reduces the ability to capture a complete profile of the HIV reports in Georgia. It also
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limits the ability to understand how effective ART is on HIV viral suppression. Because
scientific data has shown that consistent HIV treatment is key for HIV viral suppression,
Georgia can only assume that individuals who were virally suppressed were consistently
taking ART.
Because hepatitis data and HIV data are housed in two separate databases, a
manual match between the two databases had to be performed to identify the people with
coinfections. Because the hepatitis database also experiences underreporting, there were
several gaps in identifying cases for inclusion as a coinfected diagnoses. Diagnoses with
hepatitis infection and undiagnosed HIV infection would not be included, and diagnoses
with HIV infection and undiagnosed hepatitis infection would also not be included in the
study database.
Finally, there may have been overlap with successfully treated hepatitis infection
and subsequently diagnosed HIV infection. Unlike HIV data, hepatitis data are not
continuously reported with updated lab data. So ultimately there is no way to identify if a
case which was reported as HBV or HCV positive had been successfully treated and
cleared or if the case was not treated and became a chronic hepatitis infection.

Recommendations for Future Research
Due to data limitations, the current study was unable to verify the HIV treatment
status of the cases. To assess if the HIV/hepatitis coinfected individuals are more likely to
be HIV virally suppressed than individuals infected with HIV only due to their likelihood
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of adhering to HIV treatment, future research on ART adherence in this population is
recommended.
It is likely that socioeconomic confounders existed among the individuals in the
current study that predisposed them to be susceptible to a more rapid progression to
AIDS. Such socioeconomic confounders could be education, employment status,
occupation, income level, and presence/absence of insurance. These variables are not
collected as part of GDPH disease surveillance. Future research should consider
collection of such socioeconomic variables to minimize the effects of confounding due to
these factors.
Recommendations of Action
Possibly one of the greatest approaches to reduce the incidence of the
HBV/HCV/HIV coinfection is screening. HIV infected persons should be screened
regularly for HBV and HCV coinfections and advised about prevention, especially in
high-risk groups such as MSM and IDUs. Sexual transmission of HBV and HCV should
be included in counseling for HIV infected persons. Increased progression rates to AIDS
in the coinfected population may require earlier and advanced treatment of both
infections.
Implications for Social Change
The current study has shown evidence that HIV viral suppression rates are higher
in the HBV/HCV/HIV coinfected population; however, it also revealed that this
population is more prone to rapid progression to AIDS. CD4 cell counts, which are used
as indicators of AIDS, are relative predictors of mortality in persons infected with HIV,
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regardless of how long treatment has been administered or whether a person is currently
HIV virally suppressed (Brennan et al., 2013). Data from the current study could be used
to support an increase in screening, diagnosis, and access to treatment to properly care for
the HIV/HBV/HCV coinfection population.
Conclusion
The HBV/HCV/HIV coinfection has become increasingly common within the
HIV population. The coinfection of these viruses increases the morbidity and mortality
beyond those caused by either infection alone. The current study has provided insight that
the HBV/HCV/HIV coinfected population is at greater risk of progression to AIDS than
those only infected with HIV. This alone is a major public health threat. A better
understanding of the interactions between these viruses is critical to the development of
effective control and prevention of these common syndemic coinfections.
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